Document Detail

What are the realistic expectations of tocolytics?
MedLine Citation:
PMID:  12763123     Owner:  NLM     Status:  MEDLINE    
Preterm birth, the leading cause of neonatal morbidity and mortality worldwide, is a major public health problem in terms of loss of life, long term disability (e.g. cerebral palsy, chronic lung disease), and health-care costs. The outcome of preterm infants is directly related to the gestational age at delivery. The goal of tocolytic therapy is to reduce neonatal morbidity and mortality by delaying delivery, to allow for the administration of corticosteroids and/or the safe transfer to a tertiary-care centre. However, currently available tocolytics in Canada (ritodrine, indomethacin, calcium antagonists, magnesium sulphate) have poor efficacy, have not been shown to increase the completion of a course of corticosteroids, are potentially associated with significant maternal/fetal side effects, and most importantly, have not been shown to improve neonatal outcomes. At the Canadian Tocolysis Consensus Conference, there was general agreement that recommendations should be based on good quality research evidence, particularly that of randomised clinical trials when available. It was concluded that there is little evidence to support the use of any of the currently available tocolytics; tocolytic use has not been associated with improved perinatal outcomes and often have detrimental effects on the mother. Therefore, questionable efficacy and potentially serious side effects may outweigh their use. Any new tocolytic demonstrated to improve neonatal outcome will have an immediate impact on societal and long term public health-care costs.
Graeme N Smith
Related Documents :
12516743 - Therapies administered to mothers at risk for preterm birth and neurodevelopmental outc...
11896513 - Multiple courses of antenatal corticosteroids are associated with early severe lung dis...
10101383 - Differential mortality in new york city (1988-1992). part one: excess mortality among n...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  110 Suppl 20     ISSN:  1470-0328     ISO Abbreviation:  BJOG     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-05-23     Completed Date:  2003-07-10     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  England    
Other Details:
Languages:  eng     Pagination:  103-6     Citation Subset:  AIM; IM    
Department of Obstetrics and Gynaecology, Pharmacology and Toxicology, Queen's University, Kingston, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Drug Therapy, Combination
Evidence-Based Medicine
Obstetric Labor, Premature / prevention & control*
Pregnancy Outcome
Risk Assessment
Risk Factors
Tocolytic Agents / therapeutic use*
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Tocolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The case for tocolysis in threatened preterm labour.
Next Document:  The development and introduction of anti-oxytocic tocolytics.